Psychopharmacology in fragile X syndrome—Present and future

Wiley - Tập 10 Số 1 - Trang 42-48 - 2004
Elizabeth Berry‐Kravis1, Kristina Potanos2
1Department of Pediatrics, Neurology, and Biochemistry, RUSH-University Medical Center, Chicago, Illinois 60612, USA.
2Department of Pediatrics, Neurology, and Biochemistry, RUSH‐University Medical Center, Chicago, Illinois

Tóm tắt

AbstractIn addition to cognitive disability, fragile X syndrome (FXS) is associated with behavioral problems that are often functionally limiting. There are few controlled trials to guide treatment; however, available information does suggest that medications can be quite helpful for a number of categories of behavioral disturbance in FXS. Specifically, stimulants appear to be quite useful for management of distractibility, hyperactivity, and impulsive behavior; antidepressants help with anxiety, obsessive‐compulsive behaviors and mood dysregulation; and antipsychotics can reduce aggression. These medications are supportive and help minimize dysfunctional behaviors and maximize functioning. As more is learned about the neural functions of FMRP, medications in the future will be expected to target specific synaptic mechanisms dysregulated in FXS brain and thus ameliorate the cognitive deficit with resultant behavioral improvements. This article summarizes knowledge about effectiveness and approaches to management of currently available psychopharmacology for behavior in FXS and discusses early leads to future treatments for cognition. MRDD Research Reviews 2004;10:42–48. © 2004 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

10.1352/0047-6765(2001)039<0259:DBPCTO>2.0.CO;2

10.1097/00004583-199103000-00013

Amaria RN, 2001, Medication use in fragile X syndrome, Mental Health Asp Dev Dis, 4, 89

10.1124/jpet.102.040360

10.1111/j.1469-8749.2002.tb00277.x

10.1054/cupe.2002.0305

Calvani M, 2001, L‐acetylcarnitine treatment on fragile X patient hyperactive behaviour, Rev Neurol, S65

Cohen IL, 1991, Effects of long‐acting propanolol on agonistic and steriotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: A double‐blind placebo‐controlled study, J Clin Psychopharmacol, 11, 398

CohenJ KerrK IaconoT et al.2002.Measuring emotion behavior change and speech in individuals with fragile X syndrome whilst taking sertraline: A pilot of tools. Procedings of the 8thInternational Fragile X Conference Chicago.

10.1097/00004583-199207000-00024

10.1002/(SICI)1098-2396(199604)22:4<332::AID-SYN4>3.0.CO;2-C

10.1073/pnas.141145998

10.1097/00004714-200110000-00005

10.1002/ajmg.1320230119

10.1002/ajmg.1320300138

Hagerman RJ, 1994, Fluoxetine therapy in fragile X syndrome, Dev Brain Dys, 7, 155

Hagerman RJ, 1995, A survey of the efficacy of clonidine in fragile X syndrome, Dev Brain Dys, 8, 336

10.1002/(SICI)1096-8628(19990402)83:4<313::AID-AJMG15>3.0.CO;2-F

10.1002/jemt.10067

Hampson RE, 1998, Facilitative effects of the ampakine CX516 on short term memory in rats: enhancement of delayed‐nonmatch‐to‐sample performance, J Neurosci, 18, 2740, 10.1523/JNEUROSCI.18-07-02740.1998

10.1023/A:1025760302598

10.1097/00004583-199109000-00021

10.1073/pnas.122205699

10.1006/exnr.1997.6581

10.1016/S0006-8993(96)01049-9

LauterbornJC BaudryM GallCM.2002.Ampakines increase BDNF expression in FMR1 knockout mice despite lower glutamate receptor levels. Procedings of the 8thInternational Fragile X Conference Chicago.

10.1006/mcne.2001.1085

10.1016/S0166-2236(00)01959-7

10.1006/exnr.1997.6447

10.1038/nn935

10.1146/annurev.neuro.25.112701.142758

10.1056/NEJMoa013171

10.1001/archpsyc.1996.01830110037005

10.1111/j.1528-1157.1999.tb00824.x

10.1111/j.1527-3458.2002.tb00228.x

Ratey J, 1991, Buspirone treatment of aggression and anxiety in mentally retarded patients: A multiple‐baseline placebo lead‐in study, J Clin Psychiatry, 52, 159

RobertsJE BaileyDB BocciaML.2002.Psychophysiological measures of arousal: documentation of treatment effects and impact of disability. Proceedings of the 8thInternational Fragile X Conference Chicago.

Rogan MT, 1997, AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired, J Neurosci, 17, 5928, 10.1523/JNEUROSCI.17-15-05928.1997

10.1038/nn746

10.1073/pnas.91.2.777

10.1002/ajmg.1320440529

10.1002/(SICI)1096-8628(19991203)87:4<366::AID-AJMG18>3.0.CO;2-F

10.1046/j.1365-2788.1996.806806.x

10.1016/S0092-8674(03)00079-5

10.1097/00004714-199210000-00010

Thông tin
Thông tin xuất bản

Wiley

Tập 10 Số 1

42-48

Thông tin tác giả